NADAC acquisition cost data for GAVILYTE-G SOLUTION. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 43386009019 | $0.005090 | 2022-12-21 | Rx |
| 43386009019 | $0.005090 | 2022-12-21 | Rx |
Generic: PEG3350/Sod Sulf,Bicarb,Cl/KCl | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $6.9M | 505,423 | 478,998 | $0.003363 |
| 2020 | $4.5M | 336,928 | 321,455 | $0.003254 |
| 2021 | $1.7M | 131,931 | 127,895 | $0.003156 |
| 2022 | $6.1M | 410,012 | 392,766 | $0.003662 |
| 2023 | $14.0M | 810,462 | 766,658 | $0.004237 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $1.6M | 91,170 | 85,868 |
| Texas | $1.1M | 64,805 | 61,224 |
| New York | $922.7K | 56,665 | 53,229 |
| Florida | $696.2K | 42,717 | 40,480 |
| Illinois | $635.9K | 37,675 | 35,924 |
| Michigan | $571.6K | 29,429 | 27,854 |
| Minnesota | $560.5K | 27,311 | 25,941 |
| Ohio | $558.7K | 33,394 | 31,705 |
| Washington | $493.1K | 26,429 | 25,157 |
| Pennsylvania | $412.9K | 23,759 | 22,710 |
| Georgia | $404.5K | 25,019 | 23,699 |
| North Carolina | $387.9K | 21,681 | 20,656 |
| Wisconsin | $384.1K | 22,043 | 21,251 |
| Massachusetts | $381.5K | 22,674 | 21,524 |
| Virginia | $365.1K | 21,989 | 21,050 |
| Arizona | $364.1K | 22,212 | 21,130 |
| Missouri | $317.3K | 19,402 | 18,381 |
| Tennessee | $279.3K | 17,077 | 16,250 |
| New Jersey | $245.4K | 14,588 | 13,882 |
| Oregon | $244.2K | 12,701 | 12,221 |
| Kentucky | $240.9K | 14,282 | 13,729 |
| Louisiana | $224.5K | 12,857 | 12,245 |
| South Carolina | $218.1K | 12,993 | 12,419 |
| Oklahoma | $187.6K | 11,042 | 10,486 |
| Alabama | $171.7K | 9,442 | 8,919 |
| Indiana | $170.5K | 10,602 | 10,144 |
| Maryland | $167.9K | 9,786 | 9,245 |
| Nevada | $143.4K | 8,986 | 8,495 |
| New Mexico | $141.6K | 7,516 | 7,109 |
| Arkansas | $124.0K | 7,106 | 6,813 |
| Kansas | $107.7K | 6,474 | 6,261 |
| Iowa | $106.1K | 6,244 | 6,007 |
| Mississippi | $105.5K | 6,158 | 5,890 |
| Connecticut | $92.8K | 6,043 | 5,664 |
| Colorado | $92.1K | 5,097 | 4,926 |
| West Virginia | $85.4K | 4,865 | 4,570 |
| North Dakota | $82.4K | 4,085 | 3,951 |
| Idaho | $76.6K | 4,459 | 4,316 |
| Nebraska | $75.9K | 4,417 | 4,223 |
| Hawaii | $70.4K | 3,803 | 3,646 |
| Utah | $69.1K | 3,643 | 3,522 |
| South Dakota | $60.0K | 3,281 | 3,181 |
| Vermont | $50.8K | 2,886 | 2,780 |
| New Hampshire | $48.6K | 2,988 | 2,838 |
| Montana | $29.8K | 1,595 | 1,544 |
| District of Columbia | $28.8K | 1,689 | 1,575 |
| Maine | $21.2K | 1,354 | 1,280 |
| Puerto Rico | $19.1K | 780 | 765 |
| Alaska | $18.5K | 891 | 841 |
| Wyoming | $14.2K | 814 | 787 |
| Delaware | $10.5K | 615 | 605 |
| Rhode Island | $7.6K | 471 | 449 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.
Explore More Data Tools
For adjacent public-data tools, methodology notes, and network updates, visit DataPeek Facts.